C9orf135 Activators
Forskolin and IBMX elevate intracellular cAMP, thereby activating PKA and other cAMP-dependent proteins that can govern gene expression, including that of C9orf135. PMA, by activating PKC, can initiate downstream effects on transcription factors, influencing the cellular transcriptional environment. Ionomycin, through its ability to increase intracellular calcium levels, may activate calcium-dependent proteins and pathways, affecting gene expression.
The chemical class also includes epigenetic modifiers such as 5-Azacytidine and Trichostatin A, which alter DNA and histone modifications, leading to a transcriptionally permissive state that can upregulate C9orf135. Retinoic acid, by binding to its nuclear receptors, exerts a broad influence on gene expression that encompasses C9orf135. Polyphenolic compound (-)-Epigallocatechin Gallate and histone deacetylase inhibitor Sodium butyrate both exert effects on cellular signaling and chromatin accessibility, potentially increasing the expression of C9orf135. Inhibitors of key signaling kinases, namely LY294002 for PI3K, PD98059 for MEK, and SP600125 for JNK, also belong to this class. By modulating their respective pathways, these inhibitors can alter the cellular signaling landscape, potentially affecting transcription factor activity and gene expression.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
Inhibits phosphodiesterases, thus preventing cAMP breakdown and promoting the activation of cAMP-dependent signaling that can upregulate C9orf135. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
Activates protein kinase C (PKC), initiating signaling cascades that can affect C9orf135 expression by modulating transcription factors. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Increases intracellular calcium, triggering pathways that can lead to the regulation of C9orf135 via calcium-sensitive signaling molecules. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
Demethylates DNA, potentially leading to the upregulation of C9orf135 expression by altering gene accessibility. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Inhibits histone deacetylases, which can result in a more open chromatin structure and increased expression of C9orf135. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
Binds to retinoic acid receptors, impacting gene expression profiles and can modulate C9orf135 levels. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
Influences various signaling molecules and pathways that can affect C9orf135 expression by modulating cellular signaling networks. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $30.00 $46.00 $82.00 $218.00 | 19 | |
Inhibits histone deacetylases, potentially causing changes in chromatin structure that lead to increased C9orf135 expression. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Inhibits PI3K, altering the PI3K/AKT pathway, which can impact the regulation of C9orf135. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
Inhibits MEK, affecting the MAPK/ERK pathway, which can lead to changes in the regulation of C9orf135. | ||||||